globenewswire.com
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that effective January 28, 2026, Achieve's board of directors approved stock option grants to purchase an aggregate of 115,000 shares of its common stock for five new employees under Achieve's 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve's common stock on January 28, 2026.
